BTSG
BrightSpring Health Services, Inc. Common Stock
BTSG's fundamentals are strong: revenue grew 23% and free cash flow grew 78%. At 39x earnings, it's trading below its usual 54x. Analysts expect that strong growth to continue, though they disagree widely on how much.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
BTSG Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Stable |
BTSG's revenue, profitability and cash flow are currently healthy, and its balance sheet is stable.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
BTSG PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 30x | $71.45 | — |
| Cheap | 38x | $69.24 | -3.1% |
| Current | 39x | $71.45 | — |
| Fair | 53x | $98.23 | +37% |
| Expensive | 72x | $132 | +84% |
Historical ranges are pointers, not guarantees.
BTSG's PE is in its cheap range at 39x. If earnings grow as analysts expect, today's price would be 30x next year's earnings.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
BTSG Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Improving | |
| Limited | |
| Low |
BTSG has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
BTSG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.37 | +29% |
| Q3 2026 | $1.84 | +188% |
| Q2 2026 | $1.65 | +385% |
| Q1 2026 | $1.40 | +352% |
| Q4 2025 | $0.87 | +$0.96 |
| Q3 2025 | $0.64 | +$0.88 |
| Q2 2025 | $0.34 | +$1.30 |
| Q1 2025 | $0.31 | +$1.34 |
| Q4 2024 | -$0.09 | +$0.80 |
BTSG has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
BTSG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $4.2B | +26% |
| Q2 2026 | $3.9B | +23% |
| Q1 2026 | $3.6B | +26% |
| Q4 2025 | $3.6B | +16% |
| Q3 2025 | $3.3B | +15% |
| Q2 2025 | $3.1B | +15% |
| Q1 2025 | $2.9B | +12% |
| Q4 2024 | $3.1B | +29% |
BTSG's revenue has grown year over year every quarter since late 2020: $4.2B last quarter, up 26% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.8% | +1.2 points |
| Q2 2026 | 3.4% | +1.8 points |
| Q1 2026 | 3.4% | +1.6 points |
| Q4 2025 | 3% | +0.5 points |
| Q3 2025 | 2.6% | +0.7 points |
| Q2 2025 | 1.5% | -0.8 points |
| Q1 2025 | 1.8% | +1.4 points |
| Q4 2024 | 2.6% | -0.3 points |
BTSG has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over BTSG on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
BTSG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $182.2M | +98% |
| Q2 2026 | $14.9M | -40% |
| Q1 2026 | $101.4M | +21% |
| Q4 2025 | $193.9M | +157% |
| Q3 2025 | $92.2M | +1180% |
| Q2 2025 | $24.7M | +$63.6M |
| Q1 2025 | $84M | +$184.6M |
| Q4 2024 | $75.3M | -48% |
BTSG generated $492M in free cash flow over the past year, up 78% from the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over BTSG on cash flow, with more consistent year-over-year improvement.
BTSG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -50K shares |
| 1 year | +1% | +2.2M shares |
| 3 years | +29% | +49M shares |
| 5 years | +29% | +49M shares |
| Available history | +53% | +76.1M shares |
BTSG has 220M diluted shares, up 1% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $60M |
| Q1 2026 | $60M |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | $325,000 |
| Q1 2024 | $325,000 |
| Q4 2023 | $325,000 |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over BTSG on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
BTSG Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.2x | Moderate |
| Q2 2026 | 2.7x | Moderate |
| Q1 2026 | 3.1x | Elevated |
| Q4 2025 | 5.3x | High |
| Q3 2025 | 5.3x | High |
| Q2 2025 | 5.8x | High |
| Q1 2025 | 5.6x | High |
| Q4 2024 | 6.2x | High |
BTSG's net debt is about 2.2 years of its operating earnings (EBITDA), down from 5.3 years a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
BTSG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 66.6 | Neutral |
| Stochastic | 76.0 | Neutral |
BTSG's weekly RSI is 67 (neutral) and its Stochastic is 76 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
BTSG PE vs Healthcare Sector
| Metric | BTSG | Sector median | Relative |
|---|---|---|---|
| PE | 39x | 26x | 50% above |
| PE % | 20 | 45 | 25 pts below |
BTSG is trading at 39x earnings, a 50% premium to the Healthcare sector's median of 26x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
BTSG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $63.4 | 13% above |
| 20 week MA | $63.5 | 13% above |
| 50 week MA | $53.2 | 34% above |
| 100 week MA | $38.1 | 87% above |
BTSG has stronger trend alignment. BTSG is above 4 of 4 weekly averages versus HIMS above 0 of 5.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
BTSG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $11.0 | $17.0 | +55% |
| 2025 | $17.0 | $37.8 | +122% |
| 2026 YTD | $37.8 | $71.5 | +89% |
BTSG has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.